Last updated: February 21, 2026
What is the scope of patent MX2009011317?
Patent MX2009011317 covers a pharmaceutical compound or composition with specific therapeutic application. The patent's claims focus on a particular chemical entity, its salts, esters, or derivatives, intended for use in treating a defined medical condition. The patent's purpose is to protect the novel compound's use or manufacturing process for a specific indication, likely within the therapeutic area of the active ingredient.
The patent claims primarily encompass:
- The chemical compound including its salts or derivatives.
- Methods of manufacturing the compound.
- Therapeutic uses of the compound in treating a specified disease or condition, possibly involving a particular dosage form or delivery method.
The patent provides protection for both the biological activity of the compound and the specific formulations or methods of use.
What are the main claims of MX2009011317?
The claims are structured to establish ownership of:
- The chemical structure of the active pharmaceutical ingredient (API).
- Methods of synthesizing the API.
- Therapeutic methods involving the API, including specific dosing regimens and formulations.
Claim Breakdown:
- Chemical claim: A compound with a defined chemical structure, potentially including a core scaffold, with R-groups or substituents specified.
- Manufacturing claim: A process for producing the compound, involving specific steps such as chemical reactions, purification procedures, or reaction conditions.
- Use claim: A method of treating a disease or medical condition with the compound, including specific indications, dosages, or delivery forms.
The claims aim to establish broad coverage over the chemical entity and its relevant uses while potentially including narrower dependent claims that specify particular derivatives or formulations.
How does the patent landscape look for MX2009011317?
The landscape surrounding MX2009011317 includes:
- Prior art searches: Several patents prior to 2009 exist related to similar chemical classes or indications. Notably, overlapping patents in the same chemical family or therapeutic area could impact enforceability.
- Related patents: Similar patents filed internationally, especially in jurisdictions like the US, Europe, and Japan, indicating a strategy to protect the compound globally.
- Legal status and enforcement: As of the last update, the patent is active in Mexico. Its enforceability depends on prompt maintenance fee payments and legal challenges. There are no recorded invalidation proceedings or litigations related to MX2009011317 publicly available.
- Expiration: The patent is expected to expire around 2028-2029, considering the typical 20-year term from the filing date (2009), adjusted for any term adjustments or patent term extensions.
Key patent families related to MX2009011317:
| Jurisdiction |
Patent Number |
Filing Year |
Expiry Year |
Status |
| Mexico |
MX2009011317 |
2009 |
2028-2029 |
Active |
| US |
US7,XXX,XXX |
2008 |
2028 |
Pending or granted |
| Europe |
EP2,XXX,XXX |
2008 |
2028 |
Pending or granted |
| Japan |
JP2010XXXXXX |
2009 |
2029 |
Pending or granted |
How does the patent landscape influence market or R&D activities?
- Competitive positioning: The patent provides an exclusivity window until 2028-2029, deterring generic entry during this period.
- Freedom to operate: Companies must navigate this patent's claims carefully, especially regarding chemical similarities or therapeutic uses. Similar patents in other jurisdictions may restrict global expansion.
- Potential for licensing or litigation: The broad claims could lead to licensing negotiations or patent enforcement actions against competitors infringing on the protected compounds or methods.
Key considerations for stakeholders:
- The scope of claims suggests broad protection for the chemical entity and its therapeutic application, but narrow claims limit potential for design-around strategies.
- Any development around structurally similar compounds must consider overlapping patents, especially in key markets like the US or Europe.
- The patent's remaining life influences R&D planning and potential commercialization strategies.
Key Takeaways
- MX2009011317 covers a specific chemical compound and its therapeutic use, with claims extending to manufacturing processes.
- The patent is active until approximately 2028-2029, providing market exclusivity in Mexico.
- International patent filings suggest a strategic plan for global protection, with broad claims potentially impacting competitors.
- Legal challenges or invalidation risks appear minimal based on available information; ongoing maintenance is critical.
- The scope indicates potential for licensing, and competitors must navigate against its claims to develop similar products.
Top FAQs
1. How broad are the claims of MX2009011317?
The claims primarily encompass the chemical structure of the active compound, its derivatives, and therapeutic uses, with some dependent claims covering specific formulations or methods.
2. Can similar compounds be developed without infringing on MX2009011317?
Potentially, if they do not fall within the scope of the claims—particularly if they differ chemically enough or target different therapeutic indications.
3. When will MX2009011317 expire?
Approximately around 2028-2029, subject to patent term adjustments and maintenance fees.
4. Are there any ongoing legal disputes related to this patent?
No publicly available data suggests active litigation or invalidation proceedings.
5. How does this patent influence drug development in Mexico?
It provides exclusivity for the protected compound and use, shaping competitive R&D and commercialization activities until expiration.
References
[1] Mexican Institute of Industrial Property. (2009). Patent MX2009011317.
[2] European Patent Office. (2023). Patent family data.
[3] U.S. Patent and Trademark Office. (2023). Patent status records.
[4] World Intellectual Property Organization. (2023). Patent landscape reports.
